UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042714
Receipt number R000048752
Scientific Title Effects of consumption of the test food on maintaining muscular strength in healthy subjects: a randomized, placebo-controlled, double-blind, parallel-group comparison study
Date of disclosure of the study information 2020/12/10
Last modified on 2023/03/17 16:31:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of consumption of the test food on maintaining muscular strength in healthy subjects

Acronym

Effects of consumption of the test food on maintaining muscular strength in healthy subjects

Scientific Title

Effects of consumption of the test food on maintaining muscular strength in healthy subjects: a randomized, placebo-controlled, double-blind, parallel-group comparison study

Scientific Title:Acronym

Effects of consumption of the test food on maintaining muscular strength in healthy subjects

Region

Japan


Condition

Condition

Healthy Japanese subjects

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify the effects of consumption of the test food on the muscular strength in healthy subjects

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

The measured value of the muscle mass at 24 weeks after consumption (24w)

Key secondary outcomes

1. The measured value of the muscle mass at 12 weeks after consumption (12w)

1-2. The change of the muscle mass from screening (before consumption; Scr) to 12w and 24w.

2. The measured values and amounts of changes from Scr of the following items at 12w and 24w: grip strength, walking time, number of steps, stride length, walking rate (the number of steps per time), normal walking speed, maximum walking speed, Locomo 25 total score, visual analog scale (VAS) of Japan Low Back Pain Evaluation Questionnaire (JLEQ), JLEQ total score, body fat percentage, body fat mass, lean body mass, high sensitivity C-reactive protein (CRP), total procollagen type I N-terminal propeptide (P1NP), bone-specific alkaline phosphatase (BAP), the Japanese Orthopaedic Association (JOA) hip score (pain, range of motion, walking ability, and activities of daily living), JOA shoulder score (pain, function, range of motion, X-ray score, and joint stability score), JOA lumbar spine score (subjective symptoms score, objective symptoms score ,activities of daily living, and urinary bladder function)

3. The measured values of the scores of the questionnaire (each item of Locomo 25, JLEQ, JOA hip score, JOA shoulder score, and JOA lumbar spine score) at 12w and 24w


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Duration: 24 weeks
Test food: Tablet containing salmon nasal cartilage-derived proteoglycan
Administration: Take one tablet after dinner with water

* Daily dose should be taken within the day. If you forget to take the capsule, take it as soon as you remember within the day.

Interventions/Control_2

Duration: 24 weeks
Test food: Placebo
Administration: Take one tablet after dinner with water

* Daily dose should be taken within the day. If you forget to take the capsule, take it as soon as you remember within the day.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Japanese

2. Male or female aged 20 or more

3. Healthy subjects

4. Subjects who feel declining in their muscular strength

5. Subjects who are judged as eligible to participate in the study by the physician

6. Subjects who satisfy more than two conditions out of the following conditions will be excluded from this study
a. grip strength is less than 28 kg (males), or less than 18 kg (females)
b. normal walking speed is less than 1 m/s
c. skeletal muscle mass is less than 7.0 kg/m2 (males), or less than 5.7 kg/m2 (females)

7. Subjects who have relatively low values of the muscle mass

Key exclusion criteria

1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction

2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD)

3. Subjects who currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases

4. Subjects who are diagnosed with sarcopenia

5. Subjects who take ""Foods for Specified Health Uses,"" ""Foods with Functional Claims,"" or other functional food/beverage in daily use

6. Subjects who currently taking medications (including herbal medicines) and supplements

7. Subjects who are allergic to medicines and/or the test food related products

8. Subjects who are pregnant, lactation, or planning to become pregnant

9. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial

10. Subjects who are judged as ineligible to participate in the study by the physician

Target sample size

52


Research contact person

Name of lead principal investigator

1st name Tsuyoshi
Middle name
Last name Takara

Organization

Medical Corporation Seishinkai, Takara Clinic

Division name

Director

Zip code

141-0022

Address

9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan

TEL

03-5793-3623

Email

t-takara@takara-clinic.com


Public contact

Name of contact person

1st name Naoko
Middle name
Last name Suzuki

Organization

ORTHOMEDICO Inc.

Division name

R&D Department

Zip code

112-0002

Address

2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan.

TEL

03-3818-0610

Homepage URL


Email

nao@orthomedico.jp


Sponsor or person

Institute

ORTHOMEDICO Inc.

Institute

Department

Personal name



Funding Source

Organization

NIHON PHARMACEUTICAL CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Medical Corporation Seishinkai, Takara Clinic

Nerima Medical Association, Minami-machi Clinic

Name of secondary funder(s)



IRB Contact (For public release)

Organization

the ethical committee of the Takara Clinic, Medical Corporation Seishinkai

Address

9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan.

Tel

03-5793-3623

Email

IRB@takara-clinic.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)

南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)


Other administrative information

Date of disclosure of the study information

2020 Year 12 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

56

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 11 Month 25 Day

Date of IRB

2020 Year 11 Month 25 Day

Anticipated trial start date

2020 Year 12 Month 11 Day

Last follow-up date

2021 Year 09 Month 10 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 12 Month 10 Day

Last modified on

2023 Year 03 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048752


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name